# US 2025/0367128 A1 · Biodegradable lipidoids and compositions and methods of use thereof for liver targeted delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367128 A1
- Document ID: US20250367128A1
- Status: Published application
- Kind: A1
- Application number: 18/853,162
- Filed: 2023-04-13
- Published: 2025-12-04
- Earliest claimed: 2022-04-14
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Michael Mitchell; Lulu Xue; Lili Wang; James M. Wilson; Claude Warzecha
- Web page: https://patentgrep.com/patent/US20250367128A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61K 48/0041: {the non-active part being polymeric}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described are biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoids and compositions thereof. In various embodiments, the LNP selectively targets a liver cell. In other aspects, the present invention relates to methods for in vivo delivery of therapeutic nucleic acids to the liver to prevent or treat diseases or disorders using the LNP compositions of the invention.

## Claims

### Claim 1

A composition comprising biodegradable lipid nanoparticles (LNP) useful for delivering a nucleic acid to a liver cell, the LNP being formed from:
(a) at least one ionizable lipid compound having the structure of Formula (LA), Formula (IB), or combinations thereof:
or a racemate, an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a derivative thereof;
wherein the total concentration of ionizable lipid(s) (a) in the LNP is present in a concentration range of about 1 mol % to about 99 mol %, based on the total amount of lipids in the LNP;
(b) at least one neutral phospholipid, wherein the neutral phospholipid is present in a concentration range of about 10 mol % to about 45 mol % based on the total amount of lipids in the LNP;
(c) at least one cholesterol lipid, wherein the total cholesterol lipid is in a concentration range of about 5 mol % to about 55 mol % based on the total amount of lipids in the LNP; and
(d) at least one polyethylene glycol (PEG) lipid, wherein the total PEG-lipid is in a concentration range of about 0.5 mol % to about 12.5 mol % based on the total amount of lipids in the LNP;
(e) at least one nucleic acid encapsulated in the LNP.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ionizable lipid has the structure of (IB), or a derivative thereof

### Claim 3 (depends on 1)

The composition of claim 1, wherein the ionizable lipid has the structure of (IA), or a derivative thereof

### Claim 4 (depends on 1)

The composition of claim 1, wherein the neutral phospholipid comprises dioleoylphosphatidylethanolamine (DOPE).

### Claim 5 (depends on 1)

The composition of claim 1, wherein the cholesterol lipid is a cholesterol or a cholesteryl derivate.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the PEG-lipid comprises C12-PEG2000 or C12-PEG490.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the ratio of ionizable lipid to nucleic acid in an LNP is about 5:1 to about 10:1, based on weight percentage of the lipids.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the molar (mol) ratio of a:b:c:d is about 35%:16%:46.5%:2.5%.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the nucleic acid is DNA or RNA.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the average diameter of the LNPs comprises about 50 nm to about 150 nm as determined using cryo-transmission electron microscopy (TEM).

### Claim 11 (depends on 1)

The composition according to claim 1, wherein the nucleic acid comprises a coding sequence for an editing enzyme.

### Claim 12 (depends on 11)

The composition according to claim 11, wherein the nucleic acid is an mRNA encoding a Cas9.

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The composition according to claim 11, wherein the LNP further comprises an sgRNA.

### Claim 15 (depends on 14)

The composition according to claim 14, wherein the ratio of mRNA to sgRNA is about 1:5 to 5:1 mRNA to sgRNA based on molar percentage.

### Claim 16

(canceled)

### Claim 17 (depends on 11)

The composition according to claim 11, wherein the nucleic acid encodes a synthetic or engineered nuclease, a zinc finger nuclease, a TAL-effector nuclease, or a meganuclease.

### Claim 18 (depends on 17)

The composition according to claim 17, wherein the nuclease targets transthyretin (TTR), albumin, or PCSK9.

### Claim 19 (depends on 1)

The composition according to claim 1, wherein the composition further comprises a second nucleic acid that encodes a therapeutic transgene.

### Claim 20 (depends on 19)

The composition according to claim 19, wherein the therapeutic transgene is associated with a liver enzyme disorder, a lysosomal storage disorder, a glycogen storage disease or deficiency, a urea cycle disorder, or a lipid disorder.

### Claim 21 (depends on 19)

The composition according to claim 19, wherein the second nucleic acid comprises a liver-specific promoter operably linked to a sequence encoding a therapeutic gene product or a transcript thereof.

### Claim 22 (depends on 1)

The composition according to claim 1, further comprising about 300 nM sucrose.

### Claim 23 (depends on 1)

A method of delivering a gene product to a subject in need thereof, the method comprising administering a therapeutically effectively amount of at least one biodegradable LNP composition of claim 1, wherein the nucleic acid encodes a gene product or a transcript therefor to the subject.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the method further comprises co-administering a gene therapy vector with the biodegradable LNP composition.

### Claim at position 25

25-29. (canceled)
